A novel, first-in-class small molecule therapeutic for the treatment of severe neuropathic pain. This asset represents a paradigm shift in pain management by targeting the genetically validated, yet historically undruggable, channels through a novel, indirect mechanism. This approach has demonstrated profound and durable analgesic effects in extensive preclinical models without the addiction liability, tolerance, or side effects that plague current standards of care, including opioids and gabapentinoids.

This asset is currently in the final stage of preclinical development, including all IND-enabling studies and GMP manufacturing. The primary indication will be Trigeminal Neuralgia, an orphan disease characterized by excruciating facial pain, with a clear path to expand into the broader neuropathic pain market. The asset is supported by a robust intellectual property portfolio, a Cooperative Research and Development Agreement (CRADA) with the NIH National Center for Advancing Translational Sciences (NCATS) as part of the HEAL Initiative, and a compelling preclinical data package demonstrating a high probability of technical and regulatory success.